Active	Status	Sponsor type	Region	Phase	Filter
12 Active 1 Inactive 13 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Li, Hongbin
ALKIVIA, NCT05523167 / 2021-001277-23: A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants with Active Idiopathic Inflammatory Myopathy.	Recruiting	2/3	240	Europe, Canada, Japan, US, RoW	EFG PH20 SC, PBO	argenx, argenx BV	Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome	12/26	02/27
NCT05247216: A Phase 2 Study of Hemay007 in Patients With Rheumatoid Arthritis	Completed	2	140	RoW	Hemay007 800 mg QD group, Hemay007 1200 mg QD group, Hemay007 600 mg QD group, Hemay007 placebo group	Tianjin Hemay Pharmaceutical Co., Ltd	Rheumatoid Arthritis	06/23	06/23
NCT05688696: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus	Recruiting	2	186	RoW	Orelabrutinib (Low Dose), Orelabrutinib (High Dose), Orelabrutinib Placebo	Beijing InnoCare Pharma Tech Co., Ltd.	Systemic Lupus Erythematosus, SLE	08/25	05/26
WILLOW, NCT05162586 / 2021-004648-27: The Study With M5049 in SLE and CLE (SCLE and/or DLE) Oct 2024 - Dec 2024 : Data for SLE Jul 2024 - Sep 2024 : Data for CLE	Completed	2	456	Europe, Japan, US, RoW	Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo	EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany	Systemic Lupus Erythematosus	11/24	11/24